6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).

Although these data did not reach statistical significance, it is likely that the proportion of patients achieving CR/CRi and an MRD response are underestimated, as MRD assessments were not mandated following achievement of a CR/CRi response.

also in 111,027 other papers